Private Capital Group’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$11K Sell
54
-6
-10% -$1.23K 0.01% 1014
2022
Q1
$13K Sell
60
-2
-3% -$435 ﹤0.01% 1173
2021
Q4
$15K Sell
62
-53
-46% -$13.6K ﹤0.01% 1145
2021
Q3
$33K Buy
115
+8
+7% +$2.62K 0.01% 839
2021
Q2
$37K Sell
107
-99
-48% -$30K 0.01% 797
2021
Q1
$58K Sell
206
-87
-30% -$23.5K 0.01% 575
2020
Q4
$72K Buy
293
+23
+9% +$5.93K 0.01% 624
2020
Q3
$77K Sell
270
-32
-11% -$8.93K 0.02% 536
2020
Q2
$81K Sell
302
-80
-21% -$24K 0.02% 514
2020
Q1
$121K Sell
382
-67
-15% -$20.3K 0.03% 359
2019
Q4
$133K Sell
449
-97
-18% -$26.9K 0.03% 367
2019
Q3
$127K Buy
546
+40
+8% +$9.31K 0.02% 409
2019
Q2
$147K Sell
506
-105
-17% -$24.2K 0.03% 282
2019
Q1
$144K Buy
611
+60
+11% +$18.9K 0.03% 356
2018
Q4
$166K Sell
551
-48
-8% -$15.3K 0.04% 269
2018
Q3
$211K Buy
599
+49
+9% +$16.9K 0.04% 245
2018
Q2
$159K Buy
550
+19
+4% +$5.34K 0.03% 294
2018
Q1
$145K Buy
531
+281
+112% +$87.2K 0.03% 309
2017
Q4
$178 Buy
+250
New +$80.2K 0.04% 251

Other funds holding BIIB

Private Capital Group's BIIB Position: Q2 2022 in Review

Private Capital Group reduced its Biogen (BIIB) stake by 10% in Q2 2022, selling an estimated $1.23K and leaving 54 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #1014.

Private Capital Group first reported a position in BIIB in Q4 2017 and has held it in 19 quarters since. The position peaked at $211K in Q3 2018. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

  • Private Capital Group held 54 shares of Biogen worth $11K as of Q2 2022.
  • Private Capital Group sold 6 Biogen shares in Q2 2022, an estimated $1.23K.
  • Biogen made up 0.01% of Private Capital Group's portfolio in Q2 2022, its #1014 holding.
  • Private Capital Group first reported a position in Biogen in Q4 2017 and has held it in 19 quarters since.
  • Private Capital Group's Biogen position peaked at $211K in Q3 2018.
  • 928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.